Keenan S P, Alexander D, Road J D, Ryan C F, Oger J, Wilcox P G
Dept of Medicine, University Hospital, University of British Columbia, Vancouver, Canada.
Eur Respir J. 1995 Jul;8(7):1130-5. doi: 10.1183/09031936.95.08071130.
Patients with generalized myasthenia gravis (MG) often have associated ventilatory muscle involvement. It is not known whether patients with isolated ocular muscle involvement have identifiable involvement of their ventilatory muscles. Most studies have assessed muscle involvement by measuring muscle strength; however, we hypothesized that measures of ventilatory muscle endurance may be more sensitive tests of ventilatory muscle involvement in myasthenia gravis. We studied 17 patients with myasthenia gravis (four with ocular involvement alone and 13 with varying degrees of generalized myasthenia gravis). Spirometry, ventilatory muscle strength (maximum inspiratory and expiratory pressures (MIP and MEP)) and endurance (2 min incremental threshold loading test) were measured before and 20 min after i.m. neostigmine. We compared the results with those of 10 normal controls. We found no difference between patients with isolated ocular involvement and controls. Ocular myasthenia gravis patients did not improve after neostigmine. The patients with generalized myasthenia gravis had reduced baseline ventilatory muscle strength (MIP 67 cmH2O (70% of predicted), MEP 86 cmH2O (50% of pred) and endurance (mean maximal load achieved = 246 g, mean pressure at highest load (P) = 19.4 cmH2O) compared with controls. After neostigmine, there was a significant increase in MIP in patients with generalized myasthenia gravis and a trend towards an increased MEP. As a group, the patients with generalized myasthenia gravis did not demonstrate a change in their ventilatory muscle endurance after neostigmine; however, there was considerable interpatient variability in response. We conclude that patients with isolated ocular MG have normal ventilatory muscle strength when tested conventionally.(ABSTRACT TRUNCATED AT 250 WORDS)
全身型重症肌无力(MG)患者常伴有呼吸肌受累。目前尚不清楚单纯眼肌受累的患者其呼吸肌是否存在可识别的受累情况。大多数研究通过测量肌肉力量来评估肌肉受累情况;然而,我们推测呼吸肌耐力测量可能是检测重症肌无力患者呼吸肌受累更敏感的指标。我们研究了17例重症肌无力患者(4例仅眼肌受累,13例有不同程度的全身型重症肌无力)。在肌肉注射新斯的明前及注射后20分钟测量肺活量、呼吸肌力量(最大吸气和呼气压力(MIP和MEP))和耐力(2分钟递增阈值负荷试验)。我们将结果与10名正常对照者进行比较。我们发现单纯眼肌受累患者与对照组之间无差异。眼肌型重症肌无力患者新斯的明治疗后无改善。与对照组相比,全身型重症肌无力患者的基线呼吸肌力量降低(MIP为67 cmH2O(预测值的70%),MEP为86 cmH2O(预测值的50%)),耐力降低(平均最大负荷达到 = 246 g,最高负荷时的平均压力(P) = 19.4 cmH2O)。新斯的明治疗后,全身型重症肌无力患者的MIP显著增加,MEP有增加趋势。作为一个整体,全身型重症肌无力患者新斯的明治疗后呼吸肌耐力无变化;然而,患者间的反应存在很大差异。我们得出结论,按传统方法测试时,单纯眼肌型MG患者的呼吸肌力量正常。(摘要截短至250字)